Zusammenfassung
An einem Meerschweinchenmodell der experimentellenPseudomonas aeruginosa-Pneumonie wurden die Faktoren untersucht, die die Wirksamkeit einer passiven Immunisierung mit Psomaglobin®N*, einem i.v.Pseudomonas-Immunglobulin, beeinflussen. Tiere, die 2 Stunden nach Infektion mit einer einmaligen intravenösen Infusion von Psomaglobin®N in einer Dosis von 500 mg/kg behandelt wurden, wiesen eine Überlebensrate von 33% auf. Geringere Dosen waren weniger wirksam. Keines der mit Albumin behandelten Kontrolltiere überlebte. Die Therapie mit Psomaglobin®N war wirksam, wenn sie 2 Stunden oder 8 Stunden nach der Infektion einsetzte. Begann sie erst 24 Stunden nach der Infektion, so zeigte sie dagegen keine Wirkung mehr. Neutropenische Tiere (vorangegangene Cyclophosphamid-Behandlung) überlebten nach alleiniger Behandlung mit Psomaglobin®N nicht. Bei kombinierter Therapie mit Psomaglobin®N und Tobramycin stieg die Überlebensrate im Vergleich zu einer alleinigen Tobramycin-Behandlung jedoch signifikant auf 86% gegenüber 43% (p<0,05). Diese Befunde erlauben den Schluß, daß die Gabe von Psomaglobin®N eine wirksame Therapie derP. aeruginosa-Pneumonie sein könnte.
Summary
A guinea pig model of experimentalPseudomonas aeruginosa pneumonia was used to evaluate factors affecting the efficacy of passive immune therapy with Psomaglobin®N, a hyperimmuneP. aeruginosa globulin. Animals treated 2 h after infection with a single intravenous infusion of Psomaglobin®N, 500 mg/kg, demonstrated 33% survival. Lower dosages were less effective and no survivors occurred among albumin-treated controls. Treatment with Psomaglobin®N was effective if given 2 h or 8 h after infection but not if delayed until 24 h after infection. Animals rendered neutropenic with cyclophosphamide did not survive if treated with Psomaglobin®N alone. However, when Psomaglobin®N was added to tobramycin treatment, a significant increase in survival occurred (86%) as compared to that observed with tobramycin alone (43%) (p<0.05). We conclude that Psomaglobin®N may offer a useful therapeutic option in management ofP. aeruginosa pneumonia.
Article PDF
Avoid common mistakes on your manuscript.
Literatur
Stevens, R. M., Teres, D., Skillman, J. J., Feingold, D. S. Pneumonia in an intensive care unit: a 30-month experience. Arch. Intern. Med. 134 (1974) 106–111.
Bryan, C. S., Reynolds, K. L. Bacteremic nosocomial pneumonia. Analysis of 172 episodes from a single metropolitan area. Am. Rev. Respir. Dis. 129 (1984) 668–671.
Graybill, J., Marshall, L., Charache, P., Wallace, C., Melvin, V. Nosocomial pneumonia — a continuing major problem. Am. Rev. Respir. Dis. 108 (1973) 1130–1140.
Pennington, J. E., Reynolds, H. Y., Carbone, P. P. Pseudomonas pneumonia: a retrospective study of 36 cases. Am. J. Med. 55 (1973) 155–160.
Iannini, P. B., Claffey, T., Quintiliani, R. Bacteremic pseudomonas pneumonia. J. Am. Med. Ass. 230 (1974) 558–561.
Young, L. S., Wenzel, R. P., Sabath, L. D., Pollack, M., Pennington, J. E., Platt, R. The outlook for prevention and treatment of infections due toPseudomonas aeruginosa. Rev. Infect. Dis. 6 (Suppl.) (1984) S769-S774.
Feller, I., Pierson, C. Pseudomonas vaccine and hyperimmune plasma for burned patients. Arch. Surg. 97 (1968) 225–229.
Jones, C. E., Alexander, J. W., Fisher, M. W. Clinical evaluation ofPseudomonas hyperimmune globulins. J. Surg. Res. 14 (1973) 87–96.
Alexander, J. W., Fisher, M. W. Immunization againstPseudomonas in infection after thermal injury. J. Infect. Dis. 130 (1974) 5152–5158.
Kazmierowski, J. A., Reynolds, H. Y., Kauffman, J. C., Durbin, W. A., Graw, R. G., Devlin, H. B. Experimental pneumonia due toPseudomonas aeruginosa in leukopenic dogs: prolongation of survival by combined treatment with passive antibody to pseudomonas and granulocyte transfusions. J. Infect. Dis. 135 (1977) 438–446.
Collins, M. S., Roby, R. E. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens ofPseudomonas aeruginosa. Am. J. Med. 76 (1984) 168–174.
Pennington, J. E., Pier, G. B., Small, G. Efficacy of intravenous immune globulin for treatment of experimentalPseudomonas aeruginosa pneumonia. J. Critical Care 1 (1986) 4–10.
Pennington, J. E., Pier, G. B., Sadoff, J. C., Small, G. J. Active and passive immunization strategies forPseudomonas aeruginosa pneumonia. Rev. Infect. Dis. 8 (Suppl. 4) (1986) S426-S433.
Fisher, M. W., Devlin, H. B., Gnabasik, F. J. New immunotype schema forPseudomonas aeruginosa based on protective antigens. J. Bacteriol. 98 (1969) 835–836.
Pennington, J. E., Miller, J. J. Evaluation of a new polyvalentPseudomonas vaccine in respiratory infections. Infect. Immun. 25 (1979) 1029–1034.
Cutter Biological, U. S. Patent 4, 396, 608, August 2, 1982.
Pennington, J. E., Small, G. J., Lostrom, M. E., Pier, G. B. Polyclonal and monoclonal antibody therapy for experimentalPseudomonas aeruginosa pneumonia. Infect. Immun. 54 (1986) 239–244.
Pennington, J. E. Differential effects of cyclophosphamide and cortisone acetate on bronchioalveolar phagocytic cell populations. Am. Rev. Respir. Dis. 118 (1978) 319–324.
Pennington, J. E., Johnson, C. E. Comparative activities of N-formimidoyl thienamycin, ticarcillin, and tobramycin against experimentalPseudomonas aeruginosa pneumonia. Antimicrob. Agents Chemother. 22 (1982) 406–408.
Pirofsky, B. Intravenous immune globulin therapy in hypogamma-globulinemia. A review. Am. J. Med. 76 (1984) 53–60.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pennington, J.E., Pier, G.B. Pseudomonas aeruginosa-Immunglobulin bei experimenteller Pneumonie. Infection 15 (Suppl 2), S47–S50 (1987). https://doi.org/10.1007/BF01644192
Issue Date:
DOI: https://doi.org/10.1007/BF01644192